Marpai (MRAI) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
3 Sep, 2026Executive summary
Revenue for Q2 2026 was $4.2M, down 10.5% year-over-year, primarily due to customer turnover and pruning.
Net loss for Q2 2026 was $4.6M, a 4.9% increase from Q2 2025; net loss for the first half of 2026 was $7.8M.
The company achieved lower operating costs and improved gross margin year-over-year for Q2 2026.
Debt restructuring and a $12.1M capital raise post-quarter strengthened the capital structure.
The company continues to focus on technology-driven TPA services for self-insured employers and is adapting to evolving market needs.
Financial highlights
Q2 2026 revenue: $4.2M (Q2 2025: $4.7M); H1 2026 revenue: $8.6M (H1 2025: $10.1M).
Gross margin improved to 23.9% from 16.0% year-over-year.
Q2 2026 operating loss: $3.4M; H1 2026 operating loss: $5.9M.
Q2 2026 net loss per share: $(0.18); H1 2026 net loss per share: $(0.31).
Cost of revenue decreased year-over-year, reflecting lower sales volume and claims processing expenses.
Outlook and guidance
Management projects the need for additional capital to fund operations until revenue scales to self-sufficiency.
Ongoing evaluation of funding alternatives, including equity, debt, or asset sales.
Substantial doubt exists about the company's ability to continue as a going concern over the next 12 months.
Management expects continued efficiency gains and margin improvement through AI and technology investments.
The recent capital raise is expected to support operations and strategic priorities.
Latest events from Marpai
- Q1 2026 saw revenue drop 18% and a net loss of $3.2M, with urgent liquidity and debt restructuring.MRAI
Q1 2026 - Revenue declined 36% and net loss improved, but liquidity and going concern risks remain acute.MRAI
Q4 2025 - Board seeks approval for director elections, auditor ratification, and preferred stock authorization.MRAI
Proxy Filing - Shareholders will vote on director elections, auditor ratification, and preferred stock authorization.MRAI
Proxy Filing - Facing ongoing losses and liquidity risks, the company relies on new capital to sustain operations.MRAI
Registration Filing - Q2 2025 saw revenue drop but major cost cuts, with profitability targeted for early 2026.MRAI
Q2 2025 - Q3 2024 losses narrowed as cost cuts and investments offset revenue decline and liquidity risks.MRAI
Q3 2024 - Q2 2024 saw a 28% revenue drop, $13M net loss, and a $7.6M impairment charge.MRAI
Q2 2024 - Losses narrowed in 2024; new PBM products and partnerships target 2025 profitability.MRAI
Q4 2024